Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing bla(VIM-2) and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio

Federico Perez, Case Western Reserve University
Andrea M. Hujer, Case Western Reserve University
Steven H. Marshall, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Amy J. Ray, Case Western Reserve University
Philip Rather, Emory University
Nuntra Suwantarat, University Hospitals Case Medical Center
Donald Dumford, University Hospitals Case Medical Center
Patrick O'Shea, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
T. Nicholas J. Domitrovic, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Robert A. Salata, Case Western Reserve University

Only first 10 authors above; see publication for full author list.

Journal Title: Antimicrobial Agents and Chemotherapy
Volume: Volume 58, Number 10
Publisher: American Society for Microbiology | 2014-10-01, Pages 5929-5935
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/AAC.02372-14
Permanent URL: https://pid.emory.edu/ark:/25593/s1rr5

Final published version: http://dx.doi.org/10.1128/AAC.02372-14

Copyright information:
© 2014, American Society for Microbiology. All Rights Reserved.
Accessed September 15, 2017 8:53 AM EDT
Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates Containing bla\_VIM-2 and Elements of *Salmonella* Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio

Federico Perez,\(^a,b\) Andrea M. Hujer,\(^a,b\) Steven H. Marshall,\(^a\) Amy J. Ray,\(^b,f\) Philip N. Rather,\(^b,h\) Nunta Suwantaarat,\(^f\) Donald Dumford III,\(^f\) Patrick O'Shea,\(^a\) T. Nicholas J. Domitrovic,\(^a\) Robert A. Salata,\(^b,f\) Kalyan D. Chavda,\(^f\) Liang Chen,\(^f\) Barry N. Kreiswirth,\(^f\) Alejandro J. Vila,\(^a,k\) Susanne Haussler,\(^k\) Michael R. Jacobs,\(^b,c,f\) Robert A. Bonomo,\(^a,b,d,e\)

Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA; Department of Medicine; Development of Molecular Biology and Microbiology,\(^x\) and Department of Pharmacology,\(^x\) Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; University Hospitals Case Medical Center, Cleveland, Ohio, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA; Research Service, Department of Veterans Affairs Medical Center, Decatur, Georgia, USA; Public Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA; Instituto de Biología Molecular y Celular de Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina; Hannover Medical School and Helmholtz Center for Infection Research, Hannover, Germany

Carbapenems are a mainstay of treatment for infections caused by *Pseudomonas aeruginosa*. Carbapenem resistance mediated by metallo-β-lactamases (MBLs) remains uncommon in the United States, despite the worldwide emergence of this group of enzymes. Between March 2012 and May 2013, we detected MBL-producing *P. aeruginosa* in a university-affiliated health care system in northeast Ohio. We examined the clinical characteristics and outcomes of patients, defined the resistance determinants and structure of the genetic element harboring the bla\_VIM-2 gene through genome sequencing, and typed MBL-producing *P. aeruginosa* isolates using pulsed-field gel electrophoresis (PFGE), repetitive sequence-based PCR (rep-PCR), and multilocus sequence typing (MLST). Seven patients were affected that were hospitalized at three community hospitals, a long-term-care facility, and a tertiary care center; one of the patients died as a result of infection. Isolates belonged to sequence type 233 (ST233) and were extensively drug resistant (XDR), including resistance to all fluoroquinolones, aminoglycosides, and β-lactams; two isolates were nonsusceptible to colistin. The bla\_VIM-2 gene was identified as bla\_VIM-2 contained within a class 1 integron (In559), similar to the cassette array previously detected in isolates from Norway, Russia, Taiwan, and Chicago, IL. Genomic sequencing and assembly revealed that In559 was part of a novel 35-kb region that also included a Tn501-like transposon and *Salmonella* genomic island 2 (SGI2)-homologous sequences. This analysis of XDR strains producing VIM-2 from northeast Ohio revealed a novel recombination event between *Salmonella* and *P. aeruginosa*, heralding a new antibiotic resistance threat in this region’s health care system.

Successful treatment of infections caused by *Pseudomonas aeruginosa* depends on the early administration of effective antimicrobial therapy (1). Carbapenems have been among the most active antibiotics against *P. aeruginosa*; unfortunately, carbapenem-resistant *P. aeruginosa* is increasingly prevalent (2–4). Carbapenem resistance in *P. aeruginosa* is most often caused by mechanisms associated with antibiotic-mediated selection of mutants, such as loss of the OprD porin and overexpression of cephalosporinas and efflux pumps. Additionally, *P. aeruginosa* can acquire resistance through horizontal transfer of mobile genetic elements encoding enzymes that inactivate carbapenems, including metallo-β-lactamases (MBLs) (5).

Resistance mediated by MBLs, able to hydrolyze all β-lactams except monobactams, is an emerging problem among *P. aeruginosa* isolates in many countries of Asia, Europe, Africa, and South America (6–10). One of the MBLs of foremost global importance is the Verona integron-encoded metallo-β-lactamase (VIM). Currently, MBL-mediated carbapenem resistance is infrequent in the United States although national surveillance programs have detected bla\_VIM-2 in *P. aeruginosa* and other bacteria (11–17). At the local and regional levels, the early detection of MBL-producing bacteria by clinical microbiology laboratories and the molecular characterization of these bacteria can help inform efforts to prevent and control their dissemination.

Here, we report the dissemination of *P. aeruginosa* isolates containing VIM-2 in patients from community hospitals in northeast Ohio. These isolates displayed an extensively drug resistant (XDR) phenotype, leaving few, if any, treatment options (18). As this was a “sentinel event” in our region, our objective was to define the molecular characteristics of the outbreak strain and to place it in the global context of MBL-producing *P. aeruginosa*. These analyses led us to discover a genetic element that represents a novel recombination event between elements found in *P. aeruginosa* and *Salmonella*.
**MATERIALS AND METHODS**

**Selection of bacterial isolates.** University Hospitals is an integrated health care system consisting of a tertiary care medical center, six community hospitals, and a long-term-care facility located in northeast Ohio, served by a central clinical microbiology laboratory that processes approximately 250,000 cultures a year. A laboratory-based surveillance program was established in 2007 to detect and characterize carbapenem resistance among Gram-negative bacteria across the hospital system (19). Clinical isolates of *P. aeruginosa* for which the imipenem or meropenem MIC was $>$4 µg/ml were screened for the presence of acquired carbapenemases using a modified Hodge test (mHT) with imipenem and for the presence of MBLs using imipenem-EDTA Etest strips (bioMérieux, Athens, GA). A 3-fold reduction in the imipenem MIC in the presence of EDTA triggered genetic testing for *bla*<sub>MBL</sub> (20, 21). Antimicrobial susceptibility testing (AST) was performed using the MicroScan System (Siemens, Tarrytown, NY), and results were interpreted according to Clinical and Laboratory Standards Institute guidelines (22).

**Molecular typing PFGE and rep-PCR.** Molecular typing of *P. aeruginosa* isolates containing VIM-2 was performed with pulsed-field gel electrophoresis (PFGE) using the restriction enzyme SpeI for digestion and previously described analysis criteria (23, 24). Genetic similarity of VIM-2-harboring *P. aeruginosa* isolates was also investigated by repetitive-sequence-based-PCR (rep-PCR). Bacterial DNA was extracted using an MoBio UltraClean microbial isolation kit (MoBio, Carlsbad, CA) and amplified using a DiversiLab Pseudomonas amplicon kit. Amplicons were separated by electrophoresis on microfluidic chips and analyzed on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Resulting band patterns were compared via the Pearson correlation method, using DiversiLab software (bioMérieux). Isolates with $>$95% similarity were considered genetically related (17).

**MLST.** Multilocus sequence typing (MLST) was performed on *P. aeruginosa* isolates harboring VIM-2 according to the method of Curran et al. (25). Seven housekeeping genes (*acA, aroE, gusA, mutL, nusB, ppA, and trpE*) were amplified by PCR and sequenced. Sequences were compared to existing alleles, and allelic numbers and sequence types (STs) were assigned according to the *Pseudomonas aeruginosa* public MLST database (http://pubmlst.org/paeruginosa/).

**PCR amplification and sequencing of genes encoding β-lactamases and aminoglycoside resistance enzymes.** Among isolates with a positive mHT, PCR amplification of *blaVIM*, *blaIMP*, and *blaNDM* and *blaVIM* genes was performed (26). We also tested for the presence of genes encoding aminoglycoside-modifying enzymes (AME) and 16S rRNA methyltransferases using validated primers and PCR conditions as described previously (27, 28). Amplicons were sequenced at Molecular Cloning Laboratories (MCLAB; San Francisco, CA).

**Immunoblotting.** In order to assess VIM-2 expression, rabbit polyclonal antibodies were raised against purified VIM-2 β-lactamase by New England Peptide and isolated from serum using protein G column purification (Sigma Genosys, The Woodlands, TX). Sample preparation, immunoblotting, and development were performed as previously reported (29, 30).

**Mating experiments.** To investigate the possibility of conjugative transfer of the *bla<sub>VIM</sub>* gene, *bla<sub>VIM</sub>*-containing *P. aeruginosa* isolates susceptible to rifampin were selected for by overnight growth in LB medium along with rifampin-resistant *Escherichia coli* J-53 or *P. aeruginosa* PAO1 (American Type Culture Collection, Manassas, VA). After overnight culture, cells were plated on Mueller-Hinton agar plates containing 100 µg/ml ampicillin and 100 µg/ml rifampin. Colonies that subsequently grew were replated on the same selective medium and screened by PCR for the presence of *bla<sub>VIM</sub>*.

**Genome sequencing and assembly.** Further genomic analysis of the *P. aeruginosa* wound isolate from case 1 was undertaken. Genomic DNA was extracted using a Wizard genomic DNA purification kit (Promega, Madison, WI). Genomic DNA was fragmented, and genomic libraries were prepared using an Ion Xpress Plus Fragment Library Kit (Life Technologies, Carlsbad, CA). Whole-genome sequencing was performed using the Ion Torrent Personal Genome Machine (PGM) platform per the manufacturer’s instructions (Life Technologies, Carlsbad, CA). Sequencing reads were assembled into a consensus *de novo* assembly using CLC genomic workbench software (version 5.5.1; CLC Bio, Aarhus, Denmark). Based on overlapping terminal regions, the contigs were assembled into supercontigs. The *bla<sub>VIM</sub>*-harboring supercontig was extracted, and the open reading frames (ORFs) were predicted and annotated using the RAST (rast.nmpdr.org) server (31). The IS Finder database (www.is.biotoul.fr) was used to identify the names/numbers of insertion elements that were found using the RAST server. The structure of the *bla<sub>VIM</sub>*-harboring genomic island was confirmed by long-range PCRs using internal and overlapping primers.

**Nucleotide sequence accession number.** The nucleotide sequence of the *bla<sub>VIM</sub>*-harboring genomic island was deposited in GenBank under accession number KJ463833.

**RESULTS**

**Clinical characteristics and antimicrobial susceptibility testing (AST).** In the 2-year period of 2012 and 2013, the laboratory received 3,922 single-patient isolates of *P. aeruginosa*. Among these strains, the prevalence of carbapenem resistance was 20%. As part of our laboratory-based surveillance program, phenotypic testing with the mHT and imipenem/EDTA identified seven patients with MBL-producing *P. aeruginosa*, representing 0.9% of carbapenem-resistant *P. aeruginosa* isolates.

The initial isolate of MBL-producing *P. aeruginosa* (case 1) was detected in March 2012 from a wound in the foot of a 69-year-old man with type 2 diabetes mellitus who resided at a long-term-care facility; the patient also had asymptomatic bacteriuria with XDR *P. aeruginosa*. The mHT indicated carbapenemase production, and the imipenem MIC was lowered from $>$256 µg/ml to 6 µg/ml in the presence of EDTA. MBL-producing *P. aeruginosa* isolates were similarly detected in isolates from six additional patients (cases 2 to 7) between April 2012 and May 2013 (see Table S1 in the supplemental material). Case 4 had a bloodstream infection and died despite appropriate therapy with aztreonam and colistin. Case 5 was transferred to the tertiary care center from Qatar, in the Persian Gulf. Of note, case 1 was admitted to the same ward in a long-term-care facility where case 3 had resided until 4 days before. Cases 2, 4, 6, and 7 were all treated at the same community hospital, but only cases 6 and 7 had overlapping admissions. Cases 2, 6, and 7 had been residents or were discharged to a second long-term-care facility, which is associated with community hospital 2.

AST (Table 1) indicated that the nine isolates from these seven patients exhibited imipenem MICs of $>$8 µg/ml and were resistant to all other β-lactams, as well as fluoroquinolones and aminoglycosides. Isolates from cases 1, 2 (second isolate), and 3 were additionally resistant to aztreonam. Isolates from cases 1 and 3 demonstrated intermediate resistance to colistin (MIC of 4 µg/ml), whereas all isolates were susceptible to polymyxin B.

**Molecular typing, genetic analysis, and immunoblotting.** Typing with rep-PCR revealed that all isolates shared $>$95% similarity (Fig. 1). PFGE performed on six of the nine isolates demonstrated that all isolates were closely related ($<$3 band differences) (data not shown). MLST classified all isolates as *P. aeruginosa* sequence type 233 (ST233). PCR detected *bla<sub>VIM</sub>* in all MBL-producing *P. aeruginosa* isolates, while other carbapenemase genes were absent.

Attempts to transfer the *bla<sub>VIM</sub>* gene to *P. aeruginosa* PAO1 or *E. coli* J-53 were unsuccessful. A 3.2-kb Tn402-like class 1 integron fragment was amplified in all isolates with the following primers:
intI1 forward, 5′-GCAAGCGCGCAGGCGAG-3′; tmIC reverse, 5′-GAAAACCAAGGTGGGCGATC-3′. Analysis of this molecular genetic element revealed two aminoglycoside-modifying enzyme (AME) genes: aacA7, a gene conferring resistance to amikacin and tobramycin, and aacC-A5, conveying resistance to gentamicin. Other AME or 16S rRNA methyltransferase genes were not detected. Steady-state protein expression assessed by Western blot analysis revealed that the VIM-2 β-lactamase was expressed at similar levels in all isolates tested (data not shown).

**Structure of a bla\textsubscript{VIM-2}-harboring genomic island.** Further analysis of the genetic environment of the VIM-2-producing P. aeruginosa wound isolate from case 1 revealed a genomic island harboring bla\textsubscript{VIM-2} that is 34,954 bp in length and harbors 37 predicted ORFs (Fig. 2). This genomic island is integrated into the chromosome within a gene encoding the phosphate ABC transporter substrate-binding protein (PA5101 in P. aeruginosa PAO1). The whole region is bounded by 38-bp Tn3-like transposon-associated invert repeats (IRs), flanked by 6-bp duplications (TTTTCA) of the target sequence (target site duplications [TSD]). This recombinant element carries resistance to β-lactams (bla\textsubscript{VIM-2} and bla\textsubscript{OXA-4}), aminoglycosides (aadA2, aacA7, and aacC-A5), tetracycline (tetA), chloramphenicol (cmlA6 and cmlA9), trimethoprim (dfrB5), antiseptics (qacE), sulfonamides (sul1), and mercury (a mer operon) (Fig. 2).

The upstream 19-kb region is a Tn501-like transposon (~93% identical to Tn501) that includes genes encoding a transposase (tnpA) and a resolvase (tnpR), an inserted bla\textsubscript{VIM-2}-harboring class 1 integron, and a mer operon (Fig. 2). The tnpA (2,967 bp) and tnpR (561 bp) genes are 97.4% and 99.8% identical, respectively, to those of Tn501 from P. aeruginosa plasmid pVS1 (GenBank accession number Z00027). The Tn402-like class 1 integron, carrying an aacA7-bla\textsubscript{VIM-2}-dfrB5-aacC-A5 gene cassette array, is inserted downstream of the tnpR gene, generating a 5-bp duplication sequence (GCCCT) adjacent to the IR at the integrase end.

### Table 1: Antimicrobial Susceptibility of VIM-2 Producing *Pseudomonas aeruginosa*

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Date of isolation (mo-day-yr)</th>
<th>Specimen source</th>
<th>MIC (µg/ml)a</th>
<th>Aztreonamb</th>
<th>Meropenem</th>
<th>Colistinc</th>
<th>Polymyxin Bd</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3-24-12</td>
<td>Foot wound</td>
<td>&gt;16</td>
<td>&gt;8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5-4-12</td>
<td>Sputum</td>
<td>4</td>
<td>&gt;8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5-16-12</td>
<td>Urine</td>
<td>&gt;16</td>
<td>&gt;8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>9-1-12</td>
<td>Blood</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>9-17-12</td>
<td>Sputum</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>3-12-13</td>
<td>Urine</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5-7-13</td>
<td>Sputum</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

a Isolates were also resistant to piperacillin-tazobactam (MIC > 64/4 µg/ml), cefepime (MIC > 16 µg/ml), ceftazidime (MIC > 16 µg/ml), imipenem (MIC > 8 µg/ml), levofloxacin (MIC > 8 µg/ml), ciprofloxacin (MIC > 2 µg/ml), gentamicin (MIC < 8 µg/ml), tobramycin (MIC > 8 µg/ml), and amikacin (MIC > 32 µg/ml).

b The sputum isolate from case 2 and isolates from cases 4, 5, 6, and 7 were interpreted as susceptible.

c The wound isolate from case 1, both isolates from case 2, and isolates from cases 4, 5, 6, and 7 were interpreted as susceptible.

d All isolates were interpreted as susceptible.

![FIG 1](attachment:fig1.png)

FIG 1 Typing of VIM-2-producing *Pseudomonas aeruginosa* with rep-PCR demonstrates that cases 1 to 7 share ≥95% similarity. All isolates belong to sequence type 233. LTCF, long-term-care facility; Commun. Hosp., community hospital; Ctr, center.
Alarmingly, the XDR phenotype expressed by some of these isolates precluded any reliable antibiotic treatment since they even displayed intermediate resistance to colistin, an “agent of last resort.” Aztreonam, a monobactam usually stable against MBLs, was not consistently active either. Patients who were affected had multiple comorbidities, endured prolonged colonization, required long-term care, and, in one instance, had a lethal outcome from a bloodstream infection. The epidemiological link among these genetically related isolates appears to be admission to a community hospital and residence in long-term-care facilities in northeast Ohio, with the exception of a patient who was transferred to the tertiary medical center from Qatar. After the detection of MBL-producing \textit{P. aeruginosa} by the clinical microbiology laboratory, enhanced infection control precautions and contact isolation were implemented. Despite ongoing surveillance 12 months after the last case, no additional cases have been detected.

All \textit{P. aeruginosa} isolates in this report belonged to ST233 and contained \textit{bla}_{\text{VIM-2}} in the In559 cassette array. The gene array in this class 1 integron is almost identical to genes characterized in \textit{P. aeruginosa} isolates from an outbreak in 2003 at John H. Stroger, Jr., Hospital of Cook County in Chicago, IL (isolate 7052; GenBank accession number ATY943084) (12). The same genetic element was detected in Norway (GenBank accession number FM165436) in \textit{P. aeruginosa} ST233 imported from Ghana (33), in a \textit{P. aeruginosa} isolate from Taiwan (isolate S1-36) (34), and in \textit{P. aeruginosa} ST235 from Russia (GenBank accession number DQ522233). We note that \textit{P. aeruginosa} ST233 and ST235 do not share any alleles (http://pubmlst.org/\textit{paeruginosa}). Recently, the widespread dissemination of \textit{P. aeruginosa} ST235 harboring \textit{bla}_{\text{VIM-2}} in a similar array was described in Russia and its neighboring region, as well as in several Asian countries (35, 36). Other high-risk clones of VIM-producing \textit{P. aeruginosa} have also spread successfully (37); for instance, \textit{P. aeruginosa} ST175 harboring VIM-2 has been detected in Spain, France, and Central Europe (23, 38–41).

FIG 2 \textit{Tn501}-like transposon containing \textit{bla}_{\text{VIM}} proximal to an integron-like element very similar to SGI2 (GenBank accession no. KJ463833) from \textit{Salmonella enterica} subsp. enterica serovar Emek (GenBank accession no. ATY963803). Open reading frames (ORFs) are represented by arrows. The genes located in the \textit{Pseudomonas aeruginosa} chromosome are illustrated with black arrows. The genes encoding transposase or resolvase, or within IS elements are indicated by green arrows, and the genes in the \textit{mer} operon are represented with purple arrows. Shading with light blue indicates >99.5% nucleotide identity. Antimicrobial resistance genes are shown with red arrows, and the \textit{intI1} integrase gene is shown with yellow arrows. The target duplicated sequences (TTTTCA) and In559 (GCCCT) are in bold and underlined. The three 38-bp invert repeats (IRs) are shown in italics. Single-arrow lines beneath the IRs indicate the direction of the repeats. The IR at the integrase end (IRi) and the IR at the transposon end (IRt) are indicated with vertical black bars. Small black arrowheads that flank IS\textit{Pa54} in \textit{tniC} denote its 5-bp (TTAGG) direct repeats.
Further in-depth analyses of our strains revealed that the bla-
VIM-2 gene was located in a complex 35-kb genomic island, con-
sisting of integron In559 embedded in a Tn501-like transposon, and
located in the chromosome of \textit{P. aeruginosa}. Adjacent to this
structure we found genetic elements homologous to SGI2, a large
genetic element first seen in \textit{Salmonella}. Horizontal gene transfers
between \textit{Salmonella} and other nonfermenters have been previ-
ously documented in clinical isolates, but none of these transfers
resulted in a genetic element with the size and complexity of the
one we found \cite{42}. Mobile genetic elements similar to those of
\textit{Salmonella} found in our \textit{P. aeruginosa} strain have also been iden-
tified in the chromosome of \textit{Acinetobacter baumannii} \cite{43}. Our
finding raises concerns about recombination events between bac-
terial species of diverse clinical, animal, and environmental ori-
gins that may result in the propagation of antibiotic resistance
determinants \cite{44}. \textit{Salmonella enterica} carrying the VIM-2 MBL
has been detected in Morocco, where the multidrug-resistant
(MDR) \textit{P. aeruginosa} has been detected in the United States during the past decade \cite{45}. The detection of an international clone of VIM-2 producing \textit{P. aeruginosa} in different components of a health care system in our
region heralds the potential threat of widespread dissemination of
MBLs in northeast Ohio and beyond. The presence of a single
clonal and the epidemiological association with patients affected
by multiple comorbidities and heavily exposed to health care are
reminiscent of outbreaks of two other frequently carbapenem-
resistant species, \textit{A. baumannii} and \textit{Klebsiella pneumoniae}, which
emerged in the United States during the past decade \cite{46, 47}. The
dissemination of these highly resistant pathogens underscores the
vulnerability of our patients and health care system, made more
urgent by the lack of effective antibiotic therapies and the current
crisis in antibiotic development \cite{19, 48}.

At present, disciplined adherence to infection control practices and
prudent use of antibiotics remain the best strategies to prevent the
emergence of \textit{VIM}–producing \textit{P. aeruginosa}. Although efforts and
resources in this regard are increasingly deployed in the acute-
care setting, significant challenges are faced in community and
long-term-care facilities \cite{49}. This report highlights the impor-
tant role of laboratory surveillance enhanced with detailed genetic
characterization in identifying emerging resistant phenotypes at
the local and regional levels \cite{50}. These efforts led to the identifi-
cation of a novel recombination event resulting from a Tn501-like
transposon and SGI2, expanding our understanding of the molec-
ular epidemiology of MBL-producing \textit{P. aeruginosa}.

**ACKNOWLEDGMENTS**

Funds and facilities provided by the Cleveland Department of Veter-
ans Affairs, the Veterans Affairs Merit Review Program (award
1101BX0001974), and the Geriatric Research Education and Clinical
Center VISN 10 supported this work. R.A.B. and B.N.K. received
funding from the National Institute of Allergy and Infectious Diseases of
the National Institutes of Health under award numbers R01AI072219,
R01AI063517, R01AI100560, R01AI090155, and UM1AI104681. F.P. is a
Louis Stokes Scholar at Case Western Reserve University and is supported
by the Case Western Reserve University/Cleveland Clinic CTSA (award
number U1TR000439 from the National Center for Research Resources).
P.N.R. is supported by the Merit Review program and a Research Career
Scientist award from the Department of Veterans Affairs. S.H. is funded
by a European Research Council starter grant (RESISTOME 260276).

Funding organizations were not involved in the design and conduct of
the study, the collection, analysis, and interpretation of the data, or the
preparation, review, or approval of the manuscript. The content is solely
the responsibility of the authors and does not represent the official views
of the National Institutes of Health or the Department of Veterans Affairs.

**REFERENCES**

\textit{Pseudomonas aeruginosa} bloodstream infection: importance of appropri-

2008. NHSN annual update: antimicrobial-resistant pathogens associated with
healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease

broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. In-
004.

\textit{Enterobacteriaceae} isolates from patients with intra-abdominal infections
in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring
Antimicrobial Resistance Trends (SMART). Int. J. Antimi-
(12)00004-3.

5. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant \textit{Pseu-
donomas aeruginosa}: clinical impact and complex regulation of chromo-

Emerging metallo-\beta-lactamase-mediated resistances: a summary report
from the worldwide SENTRY antimicrobial surveillance program. Clin.

7. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN.
2005. Dissemination and diversity of metallo-\beta-lactamases in Latin America:
report from the SENTRY Antimicrobial Surveillance Program. Int. J. Antimi-

8. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR.
2005. Emerging epidemic of metallo-\beta-lactamase-mediated resist-

9. Rossolini GM. 2005. Acquired metallo-\beta-lactams: an increasing clin-

10. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-

producing \textit{Pseudomonas aeruginosa} isolates detected in a tertiary care

nosocomial outbreak of \textit{Pseudomonas aeruginosa} producing an integron-

13. Toleman MA, Rolston K, Jones RN, Walsh TR. 2004. \textit{bla}_{GMC-1}, an evolu-
tionarily distinct metallo-\beta-lactamase gene in a \textit{Pseudomonas aerugi-
nosa} isolate from the United States. Antimicrob. Agents Chemother. 48:

\beta-lactamase gene in a \textit{Pseudomonas aerugi-
nosa} isolate in the United States. Antimicrob. Agents Chemother. 50:


October 2014 Volume 58 Number 10 aac.asm.org 5933

VIM and \textit{Salmonella} GI2 in \textit{Pseudomonas aeruginosa}


